Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fMRI prediction of response to certolizumab pegol in rheumatoid arthritis
2013-000337-13Phase 3Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Feb 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Cimzia plus background DMARD therapy with Placebo plus background DMARD therapy (2 arms). Primary endpoint: Low disease activity during first 12 weeks by baseline CNS activity subgroup. Started Feb 2013; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-000337-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000337-13.